BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

212 related articles for article (PubMed ID: 30653139)

  • 1. RET fusion in advanced non-small-cell lung cancer and response to cabozantinib: A case report.
    Wang Y; Xu Y; Wang X; Sun C; Guo Y; Shao G; Yang Z; Qiu S; Ma K
    Medicine (Baltimore); 2019 Jan; 98(3):e14120. PubMed ID: 30653139
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Cabozantinib for the treatment of non-small cell lung cancer with KIF5B-RET fusion. An example of swift repositioning.
    Song M; Kim SH; Yoon SK
    Arch Pharm Res; 2015 Dec; 38(12):2120-3. PubMed ID: 26377589
    [TBL] [Abstract][Full Text] [Related]  

  • 3. KIF5B/RET fusion gene in surgically-treated adenocarcinoma of the lung.
    Yokota K; Sasaki H; Okuda K; Shimizu S; Shitara M; Hikosaka Y; Moriyama S; Yano M; Fujii Y
    Oncol Rep; 2012 Oct; 28(4):1187-92. PubMed ID: 22797671
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Cabozantinib in patients with advanced RET-rearranged non-small-cell lung cancer: an open-label, single-centre, phase 2, single-arm trial.
    Drilon A; Rekhtman N; Arcila M; Wang L; Ni A; Albano M; Van Voorthuysen M; Somwar R; Smith RS; Montecalvo J; Plodkowski A; Ginsberg MS; Riely GJ; Rudin CM; Ladanyi M; Kris MG
    Lancet Oncol; 2016 Dec; 17(12):1653-1660. PubMed ID: 27825636
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Response to Cabozantinib in patients with RET fusion-positive lung adenocarcinomas.
    Drilon A; Wang L; Hasanovic A; Suehara Y; Lipson D; Stephens P; Ross J; Miller V; Ginsberg M; Zakowski MF; Kris MG; Ladanyi M; Rizvi N
    Cancer Discov; 2013 Jun; 3(6):630-5. PubMed ID: 23533264
    [TBL] [Abstract][Full Text] [Related]  

  • 6. RET-rearranged lung adenocarcinomas with lymphangitic spread, psammoma bodies, and clinical responses to cabozantinib.
    Mukhopadhyay S; Pennell NA; Ali SM; Ross JS; Ma PC; Velcheti V
    J Thorac Oncol; 2014 Nov; 9(11):1714-9. PubMed ID: 25436805
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Identification of a Novel KIF5B-RET, ABHD17C-RET Double-Fusion Variant in Lung Adenocarcinoma and Response to Cabozantinib.
    Zheng Q; Fang W; Huang Y; Gan J; Zhang L
    J Thorac Oncol; 2020 Aug; 15(8):e132-e133. PubMed ID: 32718536
    [No Abstract]   [Full Text] [Related]  

  • 8. RET Fusion Lung Carcinoma: Response to Therapy and Clinical Features in a Case Series of 14 Patients.
    Sarfaty M; Moore A; Neiman V; Dudnik E; Ilouze M; Gottfried M; Katznelson R; Nechushtan H; Sorotsky HG; Paz K; Katz A; Saute M; Wolner M; Moskovitz M; Miller V; Elvin J; Lipson D; Ali S; Gutman LS; Dvir A; Gordon N; Peled N
    Clin Lung Cancer; 2017 Jul; 18(4):e223-e232. PubMed ID: 28082048
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Association Between RET Fusions and Efficacy of Pemetrexed-based Chemotherapy for Patients With Advanced NSCLC in China: A Multicenter Retrospective Study.
    Shen T; Pu X; Wang L; Yu Z; Li J; Zhang Y; Liang X; Chen H; Xu C; Song Z; Wang W
    Clin Lung Cancer; 2020 Sep; 21(5):e349-e354. PubMed ID: 32143967
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Driver genes as predictive indicators of brain metastasis in patients with advanced NSCLC: EGFR, ALK, and RET gene mutations.
    Wang H; Wang Z; Zhang G; Zhang M; Zhang X; Li H; Zheng X; Ma Z
    Cancer Med; 2020 Jan; 9(2):487-495. PubMed ID: 31769228
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Responses to crizotinib and cabozantinib in patient with lung adenocarcinoma harboring mesenchymal-epithelial transition factor exon 14 skipping mutation: A case report.
    Qin RY; Liu LS; Zhang HY; Lu CH; Guo XY; Zhang LY; Yuan XB; Xue HH
    Medicine (Baltimore); 2021 Jan; 100(4):e24300. PubMed ID: 33530219
    [TBL] [Abstract][Full Text] [Related]  

  • 12. [Detection of ALK, ROS1 and RET fusion genes in non-small cell lung cancer patients and its clinicopathologic correlation].
    Zhong S; Zhang H; Bai D; Gao D; Zheng J; Ding Y
    Zhonghua Bing Li Xue Za Zhi; 2015 Sep; 44(9):639-43. PubMed ID: 26705279
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Phase 1 Study of Cabozantinib in Japanese Patients With Expansion Cohorts in Non-Small-Cell Lung Cancer.
    Nokihara H; Nishio M; Yamamoto N; Fujiwara Y; Horinouchi H; Kanda S; Horiike A; Ohyanagi F; Yanagitani N; Nguyen L; Yaron Y; Borgman A; Tamura T
    Clin Lung Cancer; 2019 May; 20(3):e317-e328. PubMed ID: 30718102
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Identification of a novel KIF13A-RET fusion in lung adenocarcinoma by next-generation sequencing.
    Zhang X; Li Y; Liu C; Wang W; Li M; Lv D; Sun G; Chen H; Dong X; Miao Z; Yao M; Wang K; Tian H
    Lung Cancer; 2018 Apr; 118():27-29. PubMed ID: 29571998
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Unique Genetic Characteristics and Clinical Prognosis of Female Patients with Lung Cancer Harboring RET Fusion Gene.
    Qiu Z; Ye B; Wang K; Zhou P; Zhao S; Li W; Tian P
    Sci Rep; 2020 Jun; 10(1):10387. PubMed ID: 32587276
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Neoadjuvant chemoimmunotherapy achieved a pathologic complete response in stage IIIA lung adenocarcinoma harboring
    Dai M; Wang N; Xia Q; Liao Y; Cao W; Fan J; Zhou D; Wang S; Nie X
    Front Immunol; 2023; 14():1258762. PubMed ID: 38235141
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Clinicopathological characteristics and survival of ALK, ROS1 and RET rearrangements in non-adenocarcinoma non-small cell lung cancer patients.
    Song Z; Yu X; Zhang Y
    Cancer Biol Ther; 2017 Nov; 18(11):883-887. PubMed ID: 27635639
    [TBL] [Abstract][Full Text] [Related]  

  • 18. RET fusions define a unique molecular and clinicopathologic subtype of non-small-cell lung cancer.
    Wang R; Hu H; Pan Y; Li Y; Ye T; Li C; Luo X; Wang L; Li H; Zhang Y; Li F; Lu Y; Lu Q; Xu J; Garfield D; Shen L; Ji H; Pao W; Sun Y; Chen H
    J Clin Oncol; 2012 Dec; 30(35):4352-9. PubMed ID: 23150706
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Small-Cell Lung Cancer Transformation as a Mechanism of Resistance to Pralsetinib in RET-Rearranged Lung Adenocarcinoma: A Case Report.
    Gazeu A; Aubert M; Pissaloux D; Lantuejoul S; Pérol M; Ikhlef N; Bouhamama A; Franceschi T; Swalduz A
    Clin Lung Cancer; 2023 Jan; 24(1):72-75. PubMed ID: 36437214
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Clinical Characteristics and Molecular Patterns of
    Zhang K; Chen H; Wang Y; Yang L; Zhou C; Yin W; Wang G; Mao X; Xiang J; Li B; Zhang T; Fei S
    Oncol Res; 2019 May; 27(5):575-582. PubMed ID: 30131091
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 11.